权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Unique targeting of PPARβ/δ regulation for cancer prevention and therapy

癌症预防和治疗中 PPARβ/β 调节的独特靶向

基本信息

批准号：
10539245
负责人：
Andrew Patterson
金额：
$ 64.15万
依托单位：
PENNSYLVANIA STATE UNIVERSITY, THE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-06 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10539245
关键词：
APC gene Acute Antineoplastic Agents Bioinformatics Biological Markers Breast Cancer Model Cancer Model Cancer cell line Cells Colon Colon Carcinoma Colorectal Cancer Complex Coupled Data Databases Disease Disputes Dose Down-Regulation Drug Kinetics Drug Targeting Drug resistance Epithelium Evaluation Event Exhibits Feces Gene Expression Genes Genetic Genetic Transcription Genomics Genotype Goals Growth Factor Receptors Histology Human Immune checkpoint inhibitor Invaded KRAS2 gene Ligands Link Malignant Neoplasms Metabolic Metabolic Pathway Metabolism Methodology Modeling Molecular Molecular Target Morbidity - disease rate Mutation Mutation Spectra NU/NU Mouse Neoplasm Metastasis Nodal Nuclear Receptors PPAR-beta Pathway interactions Peroxisome Proliferator-Activated Receptors Pharmaceutical Preparations Phase Pre-Clinical Model Prevention Proto-Oncogenes Recurrence Recurrent disease Regulation Repression Research Resistance Role Scientist Study models Systems Analysis TP53 gene Testing Therapeutic Time Tissues Toxic effect Translational Research Tumor Promotion Tumor Suppressor Proteins United States Variant anti-cancer cancer cell cancer heterogeneity cancer prevention cancer therapy cancer type colon cancer patients colon cancer prevention colorectal cancer prevention colorectal cancer progression colorectal cancer treatment combinatorial constitutive expression dosimetry drug efficacy effective therapy efficacy evaluation fighting gain of function gene repression genetic corepressor improved inhibitor innovation insight loss of function metabolomics migration novel novel marker novel strategies overexpression personalized approach prevent receptor recruit refractory cancer stemness transcription factor translational impact tumor tumor progression tumorigenesis web platform

项目摘要

Project Summary: Precision approaches for inhibiting, preventing recurrence, or treating cancers remains a top priority in the US. While different inhibitors have made significant improvements for these purposes (e.g. immune checkpoint inhibitors, growth factor receptor inhibitors, etc.), it is clear that additional molecular targets are needed to combine with these existing therapies due to the heterogeneity of cancers and the fact that many cancers are resistant to different inhibitors. Thus, delineating new molecular mechanisms for combinatorial approaches for more precision inhibition and therapy of cancer is of high significance. The peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) has great potential as a molecular target for preventing and/or treating colorectal cancer (CRC). Typical ligands for PPARβ/δ increase and decrease target gene expression. However, more selective, repressive PPARβ/δ ligands have recently been developed that only repress gene expression rather than increase target genes. These selective repressive PPARβ/δ ligands can markedly inhibit cellular events associated with cancer inhibition, progression and metastasis. There is no dispute that selective, repressive PPARβ/δ ligands are effective anti-cancer molecules. These facts and preliminary data provide strong support and rigor of the central hypothesis of this proposal that repressing PPARβ/δ target genes by a selective, repressive ligand can modulate CRC and may be targeted for precision approaches to inhibit/treat CRC. This hypothesis will be examined by 3 Aims. Aim 1 will include PK analysis of the selective, repressive PPARβ/δ ligand DG172 of tissue concentrations over time, and phase I and phase II metabolism of the selective, repressive PPARβ/δ ligand in tissues, biofluids and tumors. Aim 2 will determine the efficacy of the selective, repressive PPARβ/δ ligand DG172 to inhibit tumorigenesis and stemness in novel orthotopic tumors models that utilize unique, genotypically variant human cancer cell lines with genotypes that exhibit resistance to standard inhibitors used to treat CRC, and gain- and loss-of-function models for PPARβ/δ. The mechanisms by which PPARβ/δ regulates stemness will also be determined. For Aim 3, we will integrate genomic and metabolomic bioinformatic analyses to elucidate how specific metabolic and tumor-promoting pathways that can be targeted by selective repressive PPARβ/δ ligands to inhibit CRC progression and treat CRC. Data from Aim 3 will be made available to scientists by developing a web-based platform to allow for systems analyses of PPARβ/δ-specific pathways that inhibit CRC. Results from these studies will have a sustained impact as they will provide new PPARβ/δ-dependent targets that might be combined with other inhibitors to develop more effective therapies, and prevent recurrence, for CRC.

项目总结：精确的方法来抑制，预防复发，或治疗癌症仍然是一个